A prothrombin gene mutation is significantly associated with venous thrombosis.
This case-control study examined the prevalence of a prothrombin gene mutation in the 3'-untranslated region (UTR) first reported by Poort et al in Dutch subjects with a history of venous thrombosis and in matched control subjects without a history of thrombosis. We tested the hypothesis that the presence of the 3'UTR prothrombin mutation would convey a higher risk of venous or arterial thrombosis and therefore would be found in a higher-than-normal percentage of subjects with a history of thrombosis. Our study included 100 subjects: 50 with a history of thrombosis (21 with venous thrombosis and 29 with arterial thrombosis, who had been recruited from an anticoagulation clinic) and 50 control subjects without a history of thrombosis. DNA from these subjects was analyzed by polymerase chain reaction and agarose gel electrophoresis. We found a statistically significant increase in the prevalence of the 3'UTR mutation in subjects with a history of venous thrombosis compared with subjects without thrombosis. The prevalence of the 3'UTR prothrombin mutation was 19% (4/21;3 heterozygous and 1 homozygous) in subjects with a history of venous thrombosis, 0% (0/29) in subjects with a history of arterial thrombosis, and 2% (1/50) in control subjects (P < .0245, by Fisher's exact test for comparison of subjects with versus those without a history of venous thrombosis). The G-->A mutation at nucleotide 20,210 in the 3'UTR was confirmed by direct DNA sequencing. The similar increased prevalence of the 3'UTR mutation in subjects with venous thrombosis in our population and in the Dutch population studied by Poort et al suggests that this mutation is an important risk factor for venous thrombosis in the general white population.
Kapur
R K
RK
Department of Medicine, State University of New York at Stony Brook, USA.
Mills
L A
LA
Spitzer
S G
SG
Hultin
M B
MB
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000453:epidemiology / Q000235:genetics; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D004198:Disease Susceptibility; D005260:Female; D005820:Genetic Testing; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009518:New York / Q000453:epidemiology; D016017:Odds Ratio; D010375:Pedigree; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D015995:Prevalence; D011516:Prothrombin / Q000235:genetics*; D012045:Regulatory Sequences, Nucleic Acid; D012307:Risk Factors; D019851:Thrombophilia / Q000453:epidemiology / Q000235:genetics*; D013924:Thrombophlebitis / Q000453:epidemiology / Q000235:genetics*; D013927:Thrombosis / Q000453:epidemiology / Q000235:genetics
D011516:Prothrombin